Business Wire

Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the ...
Business Wire

Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal ...
Seeking Alpha

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of ...

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...
Nasdaq

Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program

Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO, May 29, 2020 /PRNewswire/ - ...
ascopubs.org

Clinical Utility of a Circulating Tumor Cell–Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non ...

Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer Patients with NSCLC who had CSF collection ...